Autoimmune pancreatitis: What we know so far

Masood, Muaaz

doi:10.1002/jgh3.12688

Cited by 9 publications

(10 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, our study is the first to summarize the differences in clinical phenotypes among Chinese and Western AIP populations. The reason caused the differences between the eastern and western AIP phenotype is unclear, which may include the genetic background, environmental factor, dietary factors ( 35 ). However, there are some limitations of the study that need to be considered.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients

Jin

Chen

et al. 2022

Front. Med.

View full text Add to dashboard Cite

AimTo characterize the clinical features of autoimmune pancreatitis (AIP) in China and compare differences between our Chinese cohort and Western cohorts.MethodsThis was a retrospective study of patients with AIP that was carried out in the China-Japan Friendship Hospital between January 2010 and April 2021. We included a total of 50 patients (46 males and 4 females) aged between 27 and 86 years who fulfilled the international Consensus Diagnostic (ICD) Criteria. For comparative purposes, we included data from seven representative Western cohorts.ResultWhen comparing Chinese and Western patients, we found that obstructive jaundice was the most frequent initial symptom (68 vs. 43%, P < 0.001). Extra-pancreatic organ involvement was more common in Chinese patients (68 vs. 30%, P < 0.001). Sclerosing cholangitis was the most frequent extrapancreatic lesion (48 vs. 24%, P = 0.001). The elevation of serum IgG4 was more obvious in our cohort (86 vs. 49%, P < 0.001). Conversely, the rates of ANA-positivity were significantly higher in Western populations (17 vs. 50%, P = 0.006). With regards to imaging, diffuse swelling was significantly more common in China (44 vs. 27%, P = 0.021). Steroid therapy was used more frequently in our Chinese patients (84 vs. 59%, P = 0.001). The steroid-response rate was also significantly higher in our Chinese patients (85 vs. 54%, P = 0.001); However, the rate of resection was higher in Western cohorts (2 vs. 31%, P < 0.001). There was no significant difference between the two populations with regards to recurrence rate (33 vs. 33%, P = 1.000).ConclusionThis study identified significant differences between Chinese and Western populations of patients with AIP. Within the Chinese population, AIP was more likely to have jaundice and extra-pancreatic organ involvement, and elevated serum IgG4 levels. Chinese patients were also showed favorable responses to treatment with glucocorticoids.

show abstract

Section: Discussionmentioning

confidence: 99%

The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients

Jin

Chen

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…122,123 One of the few GI disorders for which rituximab showed a favorable response, including safety and efficacy, is autoimmune pancreatitis. [124][125][126][127][128][129][130][131][132] Patients afflicted with this disease experience remission, and consequently, relief from severe abdominal pain after rituximab treatment. Overall, rituximab provided clinical benefit in 22%…”

Section: Gastroenterologymentioning

confidence: 99%

Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases

Mostkowska,

Rousseau,

Raynal

2023

Preprint

View full text Add to dashboard Cite

Rituximab, the first monoclonal antibody approved for the treatment of lymphoma, eventually became one of the most popular and versatile drugs ever in terms of clinical application and revenue. Since its patent expiration, and consequently, the loss of exclusivity of the original biologic, its repurposing as an off-label drug has increased dramatically, propelled by the development and commercialization of its many biosimilars. Currently, rituximab is prescribed worldwide to treat a vast range of autoimmune diseases mediated by B cells. Here, we present a comprehensive overview of rituximab repurposing in 116 autoimmune diseases across 17 medical specialties, sourced from over 1,530 publications. Our work highlights the extent of its off-label use and clinical benefits, underlining the success of rituximab repurposing for both common and orphan immune-related diseases. We discuss the scientific mechanism associated with its clinical efficacy and provide additional indications for which rituximab could be investigated. Our study presents rituximab as a flagship example of drug repurposing owing to its central role in targeting CD20+ B cells in over 100 autoimmune diseases.

show abstract

“… 1 Type 1 AIP predominantly affects male adults and has multiorgan extrapancreatic manifestations (ie, sclerosing cholangitis, interstitial nephritis, sclerosing sialadenitis, mediastinal fibrosis, and thyroiditis). 2 However, it is much less associated with inflammatory bowel disease compared with type 2 AIP, which is reported to have a least 15% predilection for ulcerative colitis. 2 It is believed that the cause of AIP maybe multifactorial from immunological, genetic, and/or environmental and that an inciting event in genetically predisposed individuals may trigger AIP.…”

Section: Introductionmentioning

confidence: 99%

“… 2 However, it is much less associated with inflammatory bowel disease compared with type 2 AIP, which is reported to have a least 15% predilection for ulcerative colitis. 2 It is believed that the cause of AIP maybe multifactorial from immunological, genetic, and/or environmental and that an inciting event in genetically predisposed individuals may trigger AIP. To date, there are no reports of vaccine-induced type 1 AIP.…”

Section: Introductionmentioning

confidence: 99%

Type 1 Autoimmune Pancreatitis Unmasked by COVID-19 Vaccine

et al. 2023

View full text Add to dashboard Cite

Autoimmune pancreatitis is a rare fibro-inflammatory disease with 2 distinct subtypes of which each has their own clinical presentation, risk factors, and histopathological patterns. We present a case of newly diagnosed type 1 autoimmune pancreatitis in a symptomatic 54year-old man with stable ulcerative colitis 1 month after COVID-19 vaccination. Previous reports have indicated that vaccinations can trigger autoimmune disease in predisposed individuals. This case discusses the occurrence of autoimmune pancreatitis triggered after COVID-19 vaccination.

show abstract

Autoimmune pancreatitis: What we know so far

Cited by 9 publications

References 106 publications

The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients

The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients

Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases

Type 1 Autoimmune Pancreatitis Unmasked by COVID-19 Vaccine

Contact Info

Product

Resources

About